Anthony K.C. Chan
YOU?
Author Swipe
View article: American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Open
Background The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE …
View article: Utilizing ChatGPT-3.5 to Assist Ophthalmologists in Clinical Decision-making
Utilizing ChatGPT-3.5 to Assist Ophthalmologists in Clinical Decision-making Open
Purpose: ChatGPT-3.5 has the potential to assist ophthalmologists by generating a differential diagnosis based on patient presentation. Methods: One hundred ocular pathologies were tested. Each pathology had two signs and two symptoms prom…
View article: Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies Open
Introduction The Phase 3 studies, XTEND‐1 (NCT04161495) and XTEND‐Kids (NCT04759131), showed once‐weekly efanesoctocog alfa provided high‐sustained factor VIII (FVIII) activity levels that translated into highly effective bleed prevention …
View article: <scp>BAY</scp> 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the <scp>LEOPOLD</scp> Kids Extension Study
<span>BAY</span> 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the <span>LEOPOLD</span> Kids Extension Study Open
Objectives To report the long‐term safety and efficacy of BAY 81‐8973 in the LEOPOLD Kids extension phase. Methods Patients received BAY 81‐8973 (25–50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients…
View article: Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial Open
Novo Nordisk.
View article: Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis Open
Introduction: Venous thromboembolism (VTE) in the pediatric population is a heterogenous disease due to the variability in age, anatomical location, and comorbidities. Anticoagulation (AC) is considered the main treatment option; however, …
View article: Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study Open
Introduction Efanesoctocog alfa (formerly BIVV001) is a first-in-class high-sustained factor VIII (FVIII) replacement therapy designed to overcome the von Willebrand factor-imposed half-life ceiling. Once-weekly efanesoctocog alfa 50 IU/kg…
View article: Dual surface modification of polydimethylsiloxane (PDMS) with antithrombin-heparin complex (ATH) and tissue plasminogen activator (t-PA) for enhanced antithrombotic activity
Dual surface modification of polydimethylsiloxane (PDMS) with antithrombin-heparin complex (ATH) and tissue plasminogen activator (t-PA) for enhanced antithrombotic activity Open
Medical devices used in contact with blood trigger coagulation and activate platelets leading to thrombotic complications. To prevent these effects, systemic anticoagulants and antiplatelet agents are typically prescribed, but these agents…
View article: 44 Spotting the clotting: a 3-year national surveillance study of paediatric pulmonary thromboembolism
44 Spotting the clotting: a 3-year national surveillance study of paediatric pulmonary thromboembolism Open
Background Pulmonary thromboembolism (PE) is a rare event in the paediatric population but can be acutely life-threatening and result in chronic complications. Awareness of contemporary patterns of clinical presentation, diagnostic modalit…
View article: Effect of endothelium on the anticoagulant activity of a covalent antithrombin-heparin complex
Effect of endothelium on the anticoagulant activity of a covalent antithrombin-heparin complex Open
We developed a covalent antithrombin-heparin complex (ATH) with superior In vivo anticoagulant efficacy compared to non-covalent antithrombin (AT) + unfractionated heparin (H). Previous in vitro studies of ATH, investigating the mechanisms…
View article: 802 Assessing the Below Knee Amputation Service in a London Major Trauma Centre: An Audit
802 Assessing the Below Knee Amputation Service in a London Major Trauma Centre: An Audit Open
Aim For certain complex orthoplastic patients, a below knee amputation (BKA) is the best form of reconstruction. An audit was carried out to assess whether orthoplastic patients undergoing BKAs at a major trauma centre in London were being…
View article: Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada Open
Introduction Damoctocog alfa pegol (BAY 94–9027, Jivi®) is an extended half‐life recombinant factor (F)VIII replacement, indicated for the treatment of haemophilia A in patients aged ≥12 years. Following introduction of damoctocog alfa peg…
View article: Apixaban overdose in children: case report and proposed management. A brief communication from the Pediatric and Neonatal Thrombosis and Hemostasis SSC of ISTH
Apixaban overdose in children: case report and proposed management. A brief communication from the Pediatric and Neonatal Thrombosis and Hemostasis SSC of ISTH Open
Given the increasing use of direct oral anticoagulants, it is important to have an approach to the management of overdose of these medications.
View article: Effect of Endothelium on the Anticoagulant Activity of a Covalent Antithrombin-Heparin Complex
Effect of Endothelium on the Anticoagulant Activity of a Covalent Antithrombin-Heparin Complex Open
We have developed a covalent antithrombin-heparin complex (ATH) with superior anticoagulant properties compared to non-covalent antithrombin (AT) + unfractionated heparin (H). Previous in vitro investigations of ATH activity were done in t…
View article: OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates
OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates Open
deviation) number of injections for bleed treatment was 1.8 (5.10) pre-study versus 1.1 (0.30) on-study.Mean (95% CI) change in weekly injection frequency and consumption was -1.37 (-1.59, -1.15) doses and -35.00 (-47.82,-22.18)IU/kg, resp…
View article: OC 24.4 Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A
OC 24.4 Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A Open
bleeds in life, 10 (4%) with at least a spontaneous joint bleed.The mean annualized joint bleeding rate (AJBR) and spontaneous AJBR were 0.0155 [standard deviation (SD): 0.0317] and 0.0014 (SD: 0.0097), respectively.Lower mean FVIII levels…
View article: PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA) Open
Figure: Post-EKOS X-ray demonstrating blood flow restored to IVC and left renal vein negative contrast shadow visualized. Conclusion(s):Pediatric patients may require catheter-directed or systemic thrombolysis and anticoagulation with life…
View article: PB0777 The Risk of Thrombosis in Patients with Acute Lymphoblastic Leukemia May Be Explained by the Impact of Peripheral Blasts on Endothelial Cells: An In-Vitro Study
PB0777 The Risk of Thrombosis in Patients with Acute Lymphoblastic Leukemia May Be Explained by the Impact of Peripheral Blasts on Endothelial Cells: An In-Vitro Study Open
Background: aIIb (CD41), a lineage-specific receptor, plays an important role in hemostasis due to functional interactions with fibrinogen that promote platelet interaction and clot formation.TREM-Like Transcript-1 (TLT-1) is a lineage-spe…
View article: PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A
PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A Open
Background: Severe hemophilia A is typically treated with factor VIII (FVIII) prophylaxis or non-factor therapy, with the aim of preventing bleeds and subsequent joint and musculoskeletal disease.Aims: To collect real-world prospective tre…